

## **The impact of COVID-19 disruption to cervical cancer screening in England on excess diagnoses.**

Alejandra Castanon<sup>1</sup>, Matejka Rebolj M<sup>1a</sup>, Francesca Pesola<sup>1a</sup> and Peter Sasieni<sup>1</sup>

<sup>1</sup>King's College London, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences.

<sup>a</sup> Contributed equally

### **Abstract**

**Background:** Cervical cancer screening services in England have been disrupted by the COVID-19 pandemic.

**Methods:** Using routine statistics we estimate number of women affected by delays to screening. We used published research to estimate the proportion of screening age women with high-grade cervical intraepithelial neoplasia and progression rates to cancer. Under two scenarios we estimate the impact of COVID-19 on cervical cancer over one screening cycle (3y at ages 25-49 and 5y at ages 50-64). The duration of disruption in both scenarios is six months. In the first scenario all women have their screening interval is extended by six months. In the second some women (those who would have been screened during the disruption) miss one screening cycle, but most women have no delay.

**Results:** Both scenarios result in similar numbers of excess cervical cancers: 630 vs. 632 (both 4.3 per 100,000 women in the population). However the scenario in which some women miss one screening cycle creates inequalities - they would have much higher rates of excess cancer: 41.5 per 100,000 screened women compared to those with a six month delay (5.9 per 100,000 screened).

**Conclusion:** To ensure equity for those affected by COVID-19 related screening delays additional screening capacity will need to be paired with prioritising the screening of overdue women.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 1 **Background**

2 Cervical screening aims to identify abnormal cells in the cervix and treat them before they  
3 progress to cancer. In England, cervical screening is mostly carried out in general practice  
4 by specially trained nurses. Until December 2019, when the national roll out of HPV primary  
5 testing was completed, screening was done using liquid based cytology. Screening has  
6 been offered to women aged 25-49 at three-yearly intervals (although the plan is to extend  
7 to five-yearly with HPV testing) and to those aged 50-64 at five-yearly intervals. The age-  
8 appropriate coverage is around 72% of the eligible women.(1) In recent years, the  
9 European age-standardised incidence of cervical cancer in England for women aged 25-64  
10 has been hovering around 9.5/100,000.(1)

11  
12 Vaccination against HPV (bi-valent vaccine) was introduced in England in 2008–09 to girls  
13 aged 12–13 years (born from 1<sup>st</sup> of September 1995, to 31<sup>st</sup> of August 1996) and to a catch-  
14 up cohort aged 14–18 years (born from 1<sup>st</sup> of September 1990, to 31<sup>st</sup> of August 1995).  
15 Coverage among girls aged 12–13 years has remained around 86% since.(2)

16  
17 Due to the COVID-19 pandemic cervical cancer screening has been severely disrupted the  
18 world over. In England, invitations for screening were suspended from April 2020.(3)  
19 Although call/recall was reinitiated in June, primary care providers were given the option to  
20 delay invitations for screening for up to six months if necessary.(4) Similar disruptions to  
21 screening have been reported in other countries.(5, 6) It is likely that the second and future  
22 waves of the pandemic will result in further disruption to screening.

23  
24 As the pandemic is not yet over, it is currently unknown how quickly primary care and  
25 laboratories will be able to restore cervical screening services to pre-pandemic levels, what  
26 capacity will be available to address the screening backlog that has accumulated since GP  
27 practices closed for non-urgent face to face contact in March 2020 and how many women  
28 will be willing to take up their screening invitation in the post-COVID-19 era. Nevertheless, it  
29 is possible to estimate the size of the effect that a disruption like this is likely to have on  
30 cancer incidence, depending on the screening programme's approach to compensate for the  
31 lost opportunity to be screened.

32  
33 Assuming the health service will not be able to increase screening capacity considerably  
34 compared with previous years, it will be difficult or impossible to “catch-up” with the backlog  
35 of screening. Rather the service must choose between extending the screening interval for a  
36 whole round of the programme or trying to confine the disruption to women who have  
37 already missed being screened. Here we model the impact of delays to cervical cancer

38 screening on excess diagnosis of cervical cancers among women of screening age (25-64  
39 years) in England.

40

#### 41 Methods

42 The effect of a delay in attendance to cervical screening is explored under two scenarios.

43 For both scenarios the impact of COVID-19 on the provision of cervical cancer screening  
44 would affect services over one screening cycle (3 years in women age 25-49 and 5 years in  
45 women aged 50-64) only. The length of the disruption is the same in both scenarios, but the  
46 proportion of women affected by the delay differs in each scenario. Both scenarios assume  
47 that follow-up of women testing positive at screening before the disruption were followed up  
48 on time and that follow-up services do not experience delays once the disruption ends.

49

50 The first scenario considers a rolling delay of six months for all women in England. This  
51 means that for a single screening cycle, women would be invited for HPV testing at 3.5 or  
52 5.5 years after their previous invitation to cytology screening, depending on their age. They  
53 would resume with a standard interval thereafter. The age at which screening is offered  
54 would be permanently increased by 0.5 years (up to age 65.5y). Young women entering the  
55 programme after the disruption has been resolved would not be affected.

56

57 The second scenario assumes invitations to screening were likewise disrupted for a six-  
58 month period and that women who were due a screen during this period do not receive  
59 screening during this cycle (i.e. for 3 to 5 years depending on age). Women whose invitation  
60 was not affected by COVID-19 disruption would continue to be invited as normal.

61

62 Both scenarios assume no disruption to screening uptake once screening resumes.

63

#### 64 *Population estimates*

65 The age-specific numbers of women screened in England following an invitation for  
66 screening (in categories: “call” (first ever invitation to screening), “recall” (second and later  
67 routine invitations to screening) and “outside the programme” (predominantly women who  
68 were invited but attended 12 months or more after the invitation is issued)) as reported in the  
69 NHS Cervical Screening Programme statistics for year 2018-19(7) were used to estimate the  
70 numbers of women by age group who would have normally been routinely screened over a  
71 12-month period. In the first scenario, the number of women screened in one year was  
72 multiplied by 3 or 5 depending on the age group to obtain the total population affected by the  
73 delay. In the second scenario the affected population was half of those attending over 12  
74 months.

75

76 The national statistics was the source of data for the estimated size of the female population  
77 in mid-2019 in England by age group.(8)

78

### 79 *Population with cervical intraepithelial neoplasia*

80 To estimate the number of screened women with a high-grade cervical intraepithelial  
81 neoplasia (CIN) detectable through HPV screening, data reported from the first round of  
82 screening in the English HPV primary screening pilot was used, where by far the majority of  
83 women were unvaccinated.(9) The pilot reported that 6.6% women at the age of 25-29, 1.6%  
84 at the age of 30-49 and 0.5% at the age of 50-64 years had a CIN grade 2 or worse detected  
85 following HPV primary screening, either at baseline or at one of two early recalls.

86

87 The proportion of women estimated to have high-grade CIN was multiplied by the total  
88 population affected by the disruption, in order to obtain the number of women in whom CIN2  
89 or worse diagnoses were delayed because screening could not take place as scheduled.  
90 Estimates of the population affected were adjusted for the proportion of women aged 25-29  
91 and 30-34 who were vaccinated with three doses. The proportions of the birth cohort who  
92 were vaccinated (and the age of vaccination) were taken from the national statistics(10) and  
93 are presented in supplementary table 1. The odds ratios of being diagnosed with a CIN  
94 grade 3 or worse by age at vaccination as reported for Scotland(11) (comparing to cohorts  
95 that were not offered vaccination) were used to adjust the proportion of high-grade CIN per  
96 100,000 screened women to better reflect the detection in vaccinated cohorts. Compared to  
97 unvaccinated women, the odds of high-grade CIN were the lowest (OR=0.14) among those  
98 who were vaccinated at ages 12 or 13 years. The odds ratio increased thereafter to 0.18 in  
99 those vaccinated age 14 years, 0.29 at age 15 years, 0.27 at age 16 years, 0.55 at age 17  
100 years and 0.85 at age 18 years.

101

### 102 *Progression of CIN*

103 The proportion of high-grade CIN that would have progressed to cervical cancer in six  
104 months was estimated using progression estimates from the Landy et al.(12) modelling  
105 study. In that study, parameter sets were chosen to be consistent with the literature. They  
106 reported six-monthly progression rates from high-grade CIN to asymptomatic cancer of  
107 0.12% for women aged <30 years, 0.25% at age 30-34, 0.35% at age 35-39, 0.65% at age  
108 40-49, 0.9% at age 50-61 and 1.1% at age 62 years or more. For the second scenario,  
109 cumulative transition probabilities (following an exponential distribution)(13) up to 36 months  
110 (for women aged 25-49 years) or 60 months (for those aged 50-64) were calculated from the  
111 same six-monthly progression rates to estimate the cumulative number of women whose

112 undetected CIN would have progressed to cervical cancer during one age-appropriate  
113 screening round (supplementary table 2).

114

## 115 **Results**

116 Delaying screening for 6 months for the whole population (scenario 1) would result in  
117 approximately 10.7 million women being affected by the disruption, whereas delaying  
118 screening for an entire screening cycle (scenario 2) only to those directly affected would  
119 impact 1.5 million women (Table 1). However, both scenarios would result in very similar  
120 expected numbers of excess cancers, approximately 630 over one screening round. These  
121 cases amount to approximately 4 additional cases per 100,000 women in the general  
122 population over one screening cycle.

123

124 When only taking into account the women who were affected by the delay (i.e., those that  
125 would normally have participated in screening but were unable to do so, or could only do it  
126 with a delay), the excess cervical cancer incidence rates differed vastly between the two  
127 scenarios. Those who miss an entire round (scenario 2) would have seven times higher  
128 rates of excess cancer compared with those whose screening was delayed by 6 months  
129 (41.5 per 100,000 women compared to 5.9 respectively: Table 1).

130

131 The age-specific distribution of excess cancer diagnoses with a 6-month delay can be found  
132 in Table 2, and the results for 3- or 5-year delays are shown in Table 3. In both scenarios,  
133 women aged 40-49 years are expected to be the most affected whereas the impact to  
134 women aged 25-34 years is mitigated by vaccination against HPV 16 and 18.

135

## 136 **Discussion**

137 Cervical screening at regular intervals prevents cervical cancer.(14-16) The length of the  
138 interval typically represents the period during which the benefit of screening is observed.(15)  
139 Hence, any delays to cervical screening will negatively impact cancer diagnoses. Both  
140 scenarios modelled here resulted in about 630 excess cancers, equivalent to just over 4 per  
141 100,000 women in the population, distributed across one round of screening (i.e. 3 or 5  
142 years depending on age). However the risk of cervical cancer to an average woman who  
143 would have attended screening is seven times higher if they had to delay their screening for  
144 a whole screening round than if they had to delay screening for only 6 months.

145

146 It will be challenging to assess the impact of COVID-19 related delays by monitoring  
147 population rates of cervical cancer. The impact at a population level will be spread over a  
148 number of years. Further, given the roll-out of HPV primary screening in 2020 an initial

149 increase in cancer diagnoses is expected (because the test is more sensitive than  
150 cytology).(17) Evaluation of screening histories from women diagnosed with cervical cancer  
151 once screening services resume will provide the best evidence of the actual impact of  
152 COVID-19 delays to cervical screening.

153

154 Our model can be applied to a variety of situations that have the ability to derail a cervical  
155 screening programme in the same way as has happened with the COVID-19 pandemic. A  
156 limitation of our analysis is that we had to rely on indirectly estimated parameter for the rate  
157 of progression of CIN to cervical cancer. This is not unusual in modelling studies, but the  
158 parameters used in this study had been previously calibrated to replicate cancer rates in  
159 England.(12) We have not taken into account the effect of any delays in diagnostics and  
160 treatment of women with a positive screen, nor any drop in the coverage once screening  
161 fully resumes; both would result in additional cases of cervical cancer. Finally, we focused  
162 on the additional burden of cancer due to the disruption. Any worsening of the prognosis of  
163 screen-detectable cancers due to a delayed diagnosis was beyond the scope of our analysis  
164 but would further worsen the impact of the COVID-19 disruption.

165

166 Our results show that the overall population burden of cervical cancer does not depend on  
167 whether scenario 1 or scenario 2 takes place. The two scenarios, however, clearly differ in  
168 terms of how this burden is distributed among the population. Scenario 2 culminates in a  
169 substantially higher excess risk per affected woman. Because the CIN2/3 lesions left  
170 undetected would have a longer time to progress (compared to scenario 1), it is also more  
171 likely that the excess cancers under this scenario would be diagnosed at later stages. In the  
172 name of equity, therefore, our analysis calls for measures that ensure that women do not  
173 miss an entire screening round on account of the COVID-19 disruption, i.e. scenario 2  
174 should be avoided and scenario 1 would be preferable. Under naïve assumptions used in  
175 our model, this means that an additional 9 million women would be affected by the shorter  
176 disruption that is also not without a risk. However, this risk could be diminished in the  
177 programmes by (a temporary) increase in the screening capacity in order to clear the  
178 screening backlog (on top of the usual workload). If, for example, the screening capacity  
179 increased by 33%, it would still take 18 months to clear the 6-month backlog, but it would  
180 significantly decrease the total number of excess cancers. We note that a small increase in  
181 capacity is assumed in scenario 1 to ensure that women entering screening for the first time  
182 are not affected. Unfortunately, the demand for reagents to carryout HPV testing competes  
183 directly with the demands for COVID reagents and hence increasing screening capacity may  
184 not be feasible.

185

186 Increasing the screening capacity alone will not be sufficient. Making sure that women feel  
187 confident enough to attend for screening when they are due should be another priority. This  
188 is, again, highlighted by the seven-fold higher excess risk of cervical cancer among those  
189 who are unable or unwilling to access screening for a whole round, and highlights the  
190 importance of messaging to encourage women overdue their screen to attend as soon as  
191 possible. Unfortunately, it is often difficult for primary care providers to assess a woman's  
192 prior screening history at the time when they are offered a screening appointment.  
193 Nevertheless consideration should still be given to strategies that will allow the identification  
194 and prioritization of screening of women affected by the COVID disruption to ensure that  
195 cervical screening remains a truly equitable service.(18)

196  
197  
198



## Tables

Table 1. Excess cancers due to delays in screening. Scenario comparison

	Scenario 1	Scenario 2
Total population in England	14,677,008	14,677,008
Population affected by delayed screening	10,699,491 <sup>a</sup>	1,522,219 <sup>b</sup>
Excess cervical cancers	630	632
Rate of excess cervical cancer per 100,000 screened women	5.9	41.5
Rate of excess cervical cancer per 100,000 population	4.3	4.3

<sup>a</sup> Women who undergo screening in one screening round of 3 or 5 years, depending on age, estimated from the NHS Cervical Screening Programme statistics for year 2018-19.

<sup>b</sup> Women who undergo screening during a period of 6 months, estimated from the NHS Cervical Screening Programme statistics for year 2018-19.

Table 2. Scenario 1. Population affected and excess cancers given a rolling six-month delay to screening

Age group in 2020	Women affected by a 6-month rolling delay to screening <sup>a</sup>	Estimated number of women with CIN2/3 in population	Excess diagnoses of cervical cancer	Excess rates per 100,000 affected	Excess rates per 100,000 population
25-29	1,533,957	45,772 <sup>b</sup>	55	3.6	2.9
30-34	1,329,927	18,952 <sup>b</sup>	47	3.6	2.5
35-39	1,365,366	21,846	76	5.6	4.1
40-44	1,238,154	19,810	129	10.4	7.5
45-49	1,316,637	21,066	137	10.4	7.3
50-54	1,698,585	8,493	76	4.5	3.9
55-59	1,284,705	6,424	58	4.5	3.1
60-64	932,160	4,661	51	5.5	3.2
Total	10,699,491	147,024	630	5.9	4.3

<sup>a</sup> Women who undergo screening in one screening round of 3 or 5 years, depending on age, estimated from the NHS Cervical Screening Programme statistics for year 2018-19.

<sup>b</sup>Rate of CIN2/3 in the population adjusted for proportion vaccinated.



Table 3. Scenario 2. Population affected and excess cancer due to women having their screen delayed by 3 or 5 years, depending on age.

Age group in 2020	Women affected by delay to screening <sup>a</sup>	Estimated number of women with CIN2/3 in population <sup>b</sup>	Excess diagnosis of cervical cancer	Rates per 100,000 affected (all stages)	Rates per 100,000 population (all stages)
25-29	255,660	9427 <sup>b</sup>	68	26.5	3.6
30-34	221,655	3407 <sup>b</sup>	51	22.9	2.7
35-39	227,561	3641	76	33.2	4.0
40-44	206,359	3302	126	61.2	7.4
45-49	219,440	3511	134	61.2	7.2
50-54	169,859	849	73	43.0	3.7
55-59	128,471	642	55	43.0	3.0
60-64	93,216	466	49	52.1	3.1
Total	1,522,219	25246	632	41.5	4.3

<sup>a</sup> Women who undergo screening during a period of 6 months, estimated from the NHS Cervical Screening Programme statistics for year 2018-19.

<sup>b</sup> Rate of CIN2/3 in the population adjusted for proportion vaccinated.

## References

1. Screening & Immunisations team, NHS Digital. Cervical Screening Programme, England - 2018-2019. 2019 [Available from: <https://digital.nhs.uk/data-and-information/publications/statistical/cervical-screening-annual/england---2018-19>].
2. Public Health England (PHE). Human Papillomavirus (HPV) Vaccine Coverage in England, 2008/09 to 2013/14. A review of the full six years of the three-dose schedule. : Immunisation, Hepatitis and Blood Safety Department.; 2015 [Available from: <https://www.gov.uk/government/publications/human-papillomavirus-hpv-immunisation-programme-review-2008-to-2014>].
3. Merrifield N. NHSE to start issuing cervical screening invitations again from this month. PULSE magazine, 3 June 2020;2020 [Available from: <http://www.pulsetoday.co.uk/clinical/clinical-specialties/cancer/nhse-to-start-issuing-cervical-screening-invitations-again-from-this-month/20040892.article>].
4. Pearce C. NHS England is reviewing suspension of national screening programmes: PULSE magazine, 21 April 2020; 2020 [Available from: <http://www.pulsetoday.co.uk/clinical/clinical-specialties/cancer/nhs-england-is-reviewing-suspension-of-national-screening-programmes/20040657.article>].
5. Khanna D, Khargekar NC, Khanna AK. Implementation of Early Detection Services for Cancer in India During COVID-19 Pandemic. *Cancer Control*. 2020;27(1):1073274820960471.
6. Cancino R, Su Z, Mesa R, Tomlinson G, Wang J. The Impact of COVID-19 on Cancer-Screening: Challenges and Opportunities. *JMIR Cancer*. 2020.
7. NHS Digital. Cervical Screening Programme, England - 2018-19.; 2019.
8. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2019 [Internet]. Office for National Statistics. 2020 [cited 02 September 2020]. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2019estimates>.
9. Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. *Bmj*. 2019;364:l240.
10. Annual HPV vaccine coverage in England in 2010/11 [Internet]. Department of Health. 2012 [cited 06 August 2019]. Available from: [http://media.dh.gov.uk/network/211/files/2012/03/120319\\_HP\\_Vaccine\\_UptakeReport2010-11-revised\\_acc.pdf](http://media.dh.gov.uk/network/211/files/2012/03/120319_HP_Vaccine_UptakeReport2010-11-revised_acc.pdf).
11. Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. *Bmj*. 2019;365:l1161.
12. Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. *Int J Cancer*. 2017.
13. Naber SK, Matthijsse SM, Rozemeijer K, Penning C, de Kok IM, van Ballegooijen M. Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis. *PLoS One*. 2016;11(1):e0145548.
14. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *Journal of the National Cancer Institute*. 2008;100(9):622-9.

15. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. *British journal of cancer*. 2003;89(1):88-93.
16. Lonnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2012;21(8):1354-61.
17. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. *Bmj*. 2008;337:a1754.
18. Sasieni P. Equality and equity in medical screening: what is fair? *Lancet Gastroenterol Hepatol*. 2019;4(8):578-80.